

## Tozinameran

S

### Hypersensitivity manifested as erythema multiforme minor reaction and eosinophilia: case report

A 47-year-old woman developed hypersensitivity manifested as erythema multiforme minor reaction and eosinophilia following COVID-19 immunisation with tozinameran.

The woman, who had a history of herpes labialis, underwent COVID-19 vaccination with tozinameran [BNT162b2; *route and dosage not stated*]. She developed mild patchy maculopapular rash, injection site pruritus and disperse papules in the right axillary area 24 hours after the second dose. Thereafter, the lesions extended to the thorax, neck, abdomen, flexor surface of the upper extremities, back, thighs and groin region. Maximum extension of the lesion was noted on the fifth day following vaccination. Her papules worsened to well-defined targeted lesions and the lesions were encircled by a peripheral erythematous ring with an uniform distribution on the surfaces of the neck and acral extremities. She had intense pruritus. But, she had no fever, lip discomfort or herpes labialis lesions. Thus, she underwent a biopsy of the lesion that showed interstitial and superficial perivascular dermatitis along with lymphohistiocytic infiltration and eosinophils. Subcorneal and intraepidermal spongiotic vesicles were also observed.

The woman was treated with cetirizine on the sixth day. Her serology showed positive IgG and negative IgM for Epstein-Barr virus, Human herpesvirus 1, *Toxoplasma gondii*, Human herpesvirus 3 (varicella-zoster), cytomegalovirus, parvovirus B19 and *Mycoplasma pneumoniae*. Her laboratory test 14 days after vaccination showed mild eosinophilia. One month later, her skin lesion resolved and eosinophil count became normal. It was concluded that she had tozinameran-related hypersensitivity manifested as erythema multiforme minor reaction and eosinophilia.

de las Vecillas L, et al. Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine. *Journal of Investigational Allergology and Clinical Immunology* 32: 77-78, No. 1, 2022. Available from: URL: <http://doi.org/10.18176/jiaci.0757> 803651532